- Sections :
- Crime & Public Safety
- Restaurants & Food
- Sports
- More
Categories
Research & Science
Area residents will have a chance to enjoy some interesting night-time science later this month.
Lexicon Pharmaceuticals, Inc.'s Dr. Philip Brown, senior vice president of clinical development, recently delivered a presentation at the annual meeting of the European Neuroendocrine Tumor Society (ENETS).
The Houston Advanced Research Center has launched two unique public resources on climate change and sustainability – the Texas Climate Initiative (TCI) and Texas Climate News (TCN).
Lexicon Pharmaceuticals, Inc. has initiated a Phase 2 clinical trial of LX1031, the company's oral drug candidate for irritable bowel syndrome (IBS).
The NAA will hold its algae biofuels commercialization, research and development conference at the Sheraton North in Houston Jan. 29-30 with presentations from producers and technology providers. See www.nationalalgaeassociation.com for information.
Power3 Medical Products, Inc. has been cited by Espicom Business Intelligence Market Report as a “top company” in its new “Cancer, CNS, and Cardiovascular Biomarkers, Players, Products and Prospects” report.
Lexicon Pharmaceuticals, Inc. has completed a Phase 2A clinical trial of LX6171 in a study designed to explore the potential effects of the drug candidate in subjects with age-associated memory impairment (AAMI).
Lexicon Pharmaceuticals, Inc. has submitted an investigational new drug application to the FDA for LX4211, an oral small molecule drug candidate for type 2 diabetes.
Lexicon Pharmaceuticals, Inc. will present at the Piper Jaffray Health Care Conference and the RBC Capital Markets Healthcare Conference.
Power3 Medical Products, Inc. has filed two CIP patent applications for its BC-SeraPro™ Breast Cancer blood test and protein biomarkers for blood based diagnosis of breast cancer.
Lexicon Pharmaceuticals, Inc. has successfully completed a second Phase 1 clinical trial of LX1032, an orally-delivered small molecule drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome.
Lexicon Pharmaceuticals, Inc. will be presenting results at the American College of Rheumatology annual meeting from its Phase 1 clinical trials of LX2931.
Lexicon Pharmaceuticals, Inc. will present initial Phase 1 clinical trial results for it's rheumatoid arthritis drug candidate at the annual meeting of the American College of Rheumatology.
In a recently released study, Proellex showed no microscopic evidence of carcinogenic potential.
Power3 Medical Products, Inc. is currently conducting a 300-patient clinical validation study of its NuroPro® blood serum test for Alzheimer’s and Parkinson’s disease.
Lexicon Pharmaceuticals, Inc. has initiated formal preclinical development of a new drug candidate for glaucoma.
Lexicon Pharmaceuticals, Inc. has successfully completed a Phase 1 multiple-dose escalation study in normal volunteers with LX1031, its oral drug candidate for irritable bowel syndrome.
Repros Therapeutics Inc. has released strong results from its completed extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids.
Power3 Medical Products, Inc. has announced a new major international collaboration with the Princess Haya Biotechnology Center and the Jordan University of Science and Technology.
Repros Therapeutics Inc. has released positive results from an interim analysis of its U.S. Phase 2 endometriosis trial
